Ginkgo Bioworks Holdings (DNA) Return on Capital Employed (2021 - 2026)
Ginkgo Bioworks Holdings' (DNA) quarterly Return on Capital Employed came in at 29.86% in Q1 2026, up 807.0% YoY from 3.29% in Q1 2025, and down 2.87% on a QoQ basis from 29.03% in Q4 2025.
Ginkgo Bioworks Holdings (DNA) Return on Capital Employed (2021 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has 6 years of Return on Capital Employed data on file, last reported at 29.86% in Q1 2026.
- Quarterly Return on Capital Employed rose 807.0% year-over-year to 29.86% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 29.86% (up 807.0% YoY) and the FY2025 annual result came in at 27.35%, up 1223.0% from the prior year.
- Return on Capital Employed retreated to 29.86% in Q1 2026, from 29.03% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 26.2% in Q2 2025 to a low of 202.63% in Q3 2022.
- A 5-year average of 70.03% and a median of 51.39% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed plunged 19183 bps — and 2023, when it surged 15656 bps.
- Tracing DNA's Return on Capital Employed over 5 years: stood at 108.71% in 2022, then surged by 53 bps to 51.39% in 2023, then rose by 18 bps to 42.34% in 2024, then soared by 31 bps to 29.03% in 2025, then decreased by 3 bps to 29.86% in 2026.
- The last three Return on Capital Employed figures came in at 29.86% (Q1 2026), 29.03% (Q4 2025), and 31.07% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Ginkgo Bioworks Holdings | 432.60 Mn | 348.06 Mn | 18.44 Mn | -30.96% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -30.96% |
| Mar 31, 2026 | -29.86% |
| Dec 31, 2025 | -29.03% |
| Sep 30, 2025 | -31.07% |
| Jun 30, 2025 | -26.20% |
| Mar 31, 2025 | -37.94% |
| Dec 31, 2024 | -42.34% |
| Sep 30, 2024 | -44.09% |
| Jun 30, 2024 | -60.21% |
| Mar 31, 2024 | -56.83% |
| Dec 31, 2023 | -51.39% |
| Sep 30, 2023 | -46.07% |
| Jun 30, 2023 | -58.67% |
| Mar 31, 2023 | -76.50% |
| Dec 31, 2022 | -108.71% |
| Sep 30, 2022 | -202.63% |
| Jun 30, 2022 | -160.48% |
| Mar 31, 2022 | -128.43% |
| Dec 31, 2021 | -92.53% |
| Sep 30, 2021 | -10.80% |